NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
65 trialsNCT04008238 2026-03-06
PIPER
Institut Bergonié
Phase NA Completed
NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04794127 2026-02-18
TRABEPIO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT04383119 2026-01-02
ISG-ARTICLE
Italian Sarcoma Group
Phase 2 Recruiting
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting
NCT02234050 2025-07-10
Trabectedin for Recurrent Grade II/III Meningioma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT05597917 2025-04-04
TRABTRAP
Universität Münster
Phase 3 Recruiting
NCT06524583 2025-03-30
L-UteCIN
UNICANCER
Phase 2 Recruiting
NCT03164980 2025-03-20
COMPASS
North Eastern German Society of Gynaecological Oncology
Phase 4 Terminated
NCT03138161 2025-02-24
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 1/2 Recruiting
NCT03886311 2025-02-24
TNT
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04979442 2025-01-14
MANTRA
Rain Oncology Inc
Phase 3 Terminated
NCT03023124 2024-12-09
STRADA
Italian Sarcoma Group
Phase 2 Completed
NCT03127215 2024-05-08
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
Phase 2 Completed
NCT03884972 2023-09-25
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02275286 2023-05-31
TRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Recruiting
NCT03985722 2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Unknown
NCT05131386 2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Unknown
NCT02359474 2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03590210 2022-11-08
NiTraSarc
University Medicine Greifswald
Phase 2 Completed
NCT03074318 2022-04-29
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03690739 2022-02-24
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Terminated
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT02247544 2021-11-01
TRAVELL
Italian Sarcoma Group
Phase 2 Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT02398058 2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1 Completed
NCT02929394 2020-09-02
Trabectedin Maintenance Post 1st-line in STS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT02194231 2020-01-23
ATREUS
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01735071 2019-11-19
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT03496519 2018-10-09
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
Phase 1 Withdrawn
NCT00070109 2018-09-14
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT02672527 2018-08-16
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT01692678 2018-07-11
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT02066675 2018-04-11
TR1US
Italian Sarcoma Group
Phase 2 Completed
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT02249702 2017-12-06
TAUL
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01453283 2017-07-02
Tabectedin to Treat Children and Adolescents With Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01343277 2016-08-26
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01273493 2016-02-15
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
Janssen Research & Development, LLC
Phase 1 Completed
NCT00796120 2015-12-10
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT01104298 2015-10-27
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Terminated
NCT00027508 2015-02-24
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
PharmaMar
Phase 2 Terminated
NCT01426633 2014-12-16
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Heidelberg University
Phase 1 Completed
NCT00060944 2014-09-08
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed